GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sarepta Therapeutics Inc.
Sarepta Therapeutics is a leader in the treatment of Duchenne muscular dystrophy. Its stock price is highly volatile and driven by FDA decisions on its drugs. Its stock price is a story of scientific breakthroughs, regulatory battles, and the hopes of patients and investors.
Share prices of companies in the market segment - Dna
Sarepta is a leader in the treatment of Duchenne muscular dystrophy. Its business consists of this single therapeutic segment. We classify it as part of the DNA sector, and the chart below reflects the dynamics of the entire gene therapy industry, where a company's value depends on the approval of new drugs.
Broad Market Index - GURU.Markets
Sarepta Therapeutics is a biotech company leading the development of RNA-targeted gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. It is a component of the GURU.Markets index. The chart below represents the market. See how Sarepta shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SRPT - Daily change in the company's share price Sarepta Therapeutics Inc.
Sarepta Therapeutics shares exhibit extreme volatility, as measured by change_co. This reflects sensitivity to clinical trial results and FDA decisions. This metric is a key component of the formulas on System.GURU.Markets for analyzing risks in the biotech sector.
Daily change in the price of a set of shares in a market segment - Dna
Sarepta Therapeutics, Inc. is a leader in the treatment of Duchenne muscular dystrophy. This chart illustrates the extreme volatility of the biotech sector. Comparing it to SRPT's performance helps assess whether its dominant position in one niche makes it more or less stable than its diversified competitors.
Daily change in the price of a broad market stock, index - GURU.Markets
Sarepta is a leader in developing treatments for Duchenne muscular dystrophy. Biotech companies focused on rare diseases are a volatile niche. The chart below shows the average fluctuations in this sector, allowing you to assess the risks and potential of Sarepta shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sarepta Therapeutics Inc.
Sarepta is a leader in gene therapy development for rare neuromuscular diseases. Its year-over-year performance has been extremely volatile, reflecting both successes and failures in clinical trials, typical of this high-risk strategy.
Annual dynamics of market capitalization of the market segment - Dna
Sarepta Therapeutics, Inc. is a leader in developing gene therapies for rare muscle diseases such as Duchenne muscular dystrophy. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sarepta, a leader in the treatment of Duchenne muscular dystrophy, lives in the world of biotech, not economics. Its stock price depends on FDA decisions, clinical trial data, and the speed of drug adoption. This chart tells the story of how a scientific breakthrough in treating rare diseases can create enormous value, regardless of market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sarepta Therapeutics Inc.
The value of Sarepta, a biopharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its Duchenne muscular dystrophy treatments, as well as news about clinical trials and regulatory decisions that shape its future.
Monthly dynamics of market capitalization of the market segment - Dna
Sarepta Therapeutics is a leader in gene therapy for rare neuromuscular diseases, primarily Duchenne muscular dystrophy. It is at the forefront of medical science. The chart below illustrates the overall dynamics of the biotech sector, where the potential for revolutionary treatments is coupled with high development risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sarepta Therapeutics is a biopharmaceutical company specializing in rare genetic diseases. Its stock price is dependent on sales of existing drugs and, more importantly, the results of clinical trials of new drugs. This makes it highly volatile and dependent on news rather than general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sarepta Therapeutics Inc.
Sarepta Therapeutics' weekly performance has been a rollercoaster ride in the biotech world. The stock price of this company, which develops drugs for rare genetic diseases such as Duchenne muscular dystrophy, has reacted sharply to FDA decisions and clinical trial data.
Weekly dynamics of market capitalization of the market segment - Dna
Biotech focused on rare genetic diseases is a sector where weekly performance is driven by regulatory decisions. FDA news on a single drug can impact sentiment across the entire industry. This chart illustrates this backdrop, where Sarepta's success is incredibly significant.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sarepta Therapeutics specializes in treating rare genetic diseases, particularly Duchenne muscular dystrophy. Shares of such innovative biotech companies often move independently of the market. This chart will help you understand: is Sarepta living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
SRPT - Market capitalization of the company Sarepta Therapeutics Inc.
Sarepta's market capitalization chart is a dramatic story about a biotech pioneer in the treatment of Duchenne muscular dystrophy. Its extremely volatile chart is a cardiogram of hopes and disappointments associated with FDA decisions on its drugs. Its dynamics reflect the market's assessment of its cutting-edge science and ability to bring drugs to market for rare diseases.
SRPT - Share of the company's market capitalization Sarepta Therapeutics Inc. within the market segment - Dna
Sarepta Therapeutics is a leader in developing drugs to treat Duchenne muscular dystrophy, a rare genetic disorder. Its dominant market share reflects its scientific breakthroughs and approved drugs. Its market capitalization chart tells the story of how a focus on orphan diseases can create a multibillion-dollar company.
Market capitalization of the market segment - Dna
Sarepta Therapeutics is a leader in developing drugs to treat Duchenne muscular dystrophy and other rare genetic diseases. The chart below shows the biotech sector's market capitalization. Its volatility reflects the high stakes involved, where the approval of a new drug, as in Sarepta's case, can change the lives of patients and the fate of the company.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sarepta Therapeutics is a leader in developing gene therapy for Duchenne muscular dystrophy. Its high market capitalization reflects its dominance in this complex field. The chart below shows the economic weight a company offering hope for rare diseases can wield.
Book value capitalization of the company, segment and market as a whole
SRPT - Book value capitalization of the company Sarepta Therapeutics Inc.
Sarepta Therapeutics' book value is the capital invested in expensive clinical trials and the development of gene therapies for rare neuromuscular diseases. This is a tangible, scientific foundation that brings hope to thousands of patients. How has this innovative asset grown? The chart below shows the dynamics of investments in breakthrough technologies.
SRPT - Share of the company's book capitalization Sarepta Therapeutics Inc. within the market segment - Dna
Sarepta Therapeutics focuses on rare genetic diseases, which requires advanced R&D laboratories and gene therapy manufacturing facilities. The chart shows the share of these unique tangible assets, reflecting the physical foundation of its breakthrough research.
Market segment balance sheet capitalization - Dna
Biopharmaceuticals, as the BCap_Seg chart shows, require massive investments in R&D, not early-stage manufacturing. Sarepta Therapeutics is a prime example. Its value lies in its portfolio of patents for drugs treating rare diseases, not in its massive manufacturing base. This is the capital intensity of science, not industry.
Book value of all companies included in the broad market index - GURU.Markets
Sarepta Therapeutics' balance sheet comprises cutting-edge laboratories and manufacturing facilities for gene therapy development. Its value reflects the massive investment in physical infrastructure capable of producing some of the world's most complex and expensive drugs targeting rare genetic diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sarepta Therapeutics Inc.
Sarepta Therapeutics develops drugs to treat rare neuromuscular diseases. The company's book value is small compared to the potential value of its approved drugs and pipeline. The MvsBCap chart reflects the market's enormous expectations for its blockbuster drugs. The company's performance will depend entirely on FDA decisions and clinical trial data.
Market to book capitalization ratio in a market segment - Dna
Sarepta Therapeutics specializes in developing drugs to treat rare neuromuscular diseases. Like many biotech companies, its value depends almost entirely on the success of its drugs and scientific developments. This chart shows the significant premium it commands for its intellectual property and market prospects.
Market to book capitalization ratio for the market as a whole
Sarepta Therapeutics specializes in developing drugs for rare neuromuscular diseases. It's a classic biotech company, whose market value is based on the success of its scientific developments and patents. This chart demonstrates the huge gap between its market valuation and its book value, typical of companies at the forefront of science.
Debts of the company, segment and market as a whole
SRPT - Company debts Sarepta Therapeutics Inc.
Sarepta Therapeutics, a biopharmaceutical company focused on rare diseases, uses debt financing to conduct expensive clinical trials and commercialize its drugs. Gene therapy development requires significant investment. This chart shows how the company manages its capital on its path to developing breakthrough treatments.
Market segment debts - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases. Biopharmaceutical companies in the R&D stage require significant funding to conduct clinical trials. Debt instruments can be part of a complex financing puzzle. The chart shows how Sarepta manages capital on the path to new discoveries.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases. The chart shows how the company finances its expensive research. For a biopharma at the forefront of innovation that has yet to achieve stable profitability, debt is a significant risk. Its level reflects the degree of investor confidence in the success of its developments.
Market segment debt to market segment book capitalization - Dna
Sarepta Therapeutics specializes in gene therapy for rare diseases, which requires huge and risky investments in R&D. This chart for the biotech industry shows how the sector as a whole funds breakthrough but expensive research. It provides context for assessing the company's financial sustainability on its long journey to drug commercialization.
Debt to book value of all companies in the market
Sarepta Therapeutics is a biotech company whose funding depends on the success of clinical trials. This chart reflects the overall risk appetite in the economy. For a company without stable revenue, it helps understand how its debt or equity financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Sarepta Therapeutics Inc.
This chart of Sarepta Therapeutics, a biotech company specializing in treating rare genetic diseases, reflects high investor expectations. The high readings indicate market confidence in the success of its drugs and huge growth potential, even if current earnings are modest compared to its market capitalization.
P/E of the market segment - Dna
This chart shows the average P/E for the biotech sector, where Sarepta is a leader in its niche. The industry is valued based on future potential, which is reflected in the high average values. The chart demonstrates this overall optimism, against which Sarepta's unique portfolio of drugs is valued.
P/E of the market as a whole
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. This is at the cutting edge of science. This chart, reflecting investor risk appetite, shows how willing the market is to invest in biotech breakthroughs that can change lives but carry high clinical and financial risks.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases, such as Duchenne muscular dystrophy. The chart reflects the high investor expectations surrounding the potential of its drugs. Future revenue depends on the approval and commercial success of new drugs, making forecasts highly volatile.
%20P%2FE%20Sarepta%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sarepta-Therapeutics-Inc.&v=1772702721498 "Chart of the company's future (projected) P/E Sarepta Therapeutics Inc.")
Future (projected) P/E of the market segment - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. This chart shows future profitability expectations in the biotech sector. It helps understand how highly the market values the scientific potential of Sarepta's drugs and their future sales.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772702721501 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. It's a high-risk biotech business. This overall risk appetite chart shows how willing investors are to fund companies with cutting-edge, but not yet fully proven, technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702721504 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sarepta Therapeutics Inc.
Sarepta Therapeutics is a biotechnology company specializing in the development of drugs for the treatment of rare neuromuscular diseases, particularly Duchenne muscular dystrophy. Its revenue depends on sales of approved drugs and the success of clinical trials. This chart shows financial results directly related to scientific breakthroughs and patient access to therapy.
Profit of companies in the market segment - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. The company's success depends on the results of clinical trials. This chart reflects the state of the biotech sector, where scientific breakthroughs can lead to the creation of revolutionary drugs and huge profits.
Overall market profit
Sarepta Therapeutics specializes in developing gene therapies for the treatment of rare neuromuscular diseases. The company's value and future are determined by the success of clinical trials and regulatory approvals. This process is independent of the general economic cycles shown in the chart, making Sarepta a classic example of a biotech innovation company.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for the treatment of rare neuromuscular diseases, particularly Duchenne muscular dystrophy. Future revenue depends on the success of clinical trials and the approval of its high-priced drugs. This chart reflects analyst expectations regarding the breakthrough potential of Sarepta's technologies and their commercialization.
%20profit%20of%20the%20company%20Sarepta%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sarepta-Therapeutics-Inc.&v=1772702721575 "Graph of future (projected) profit of the company Sarepta Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. The company's future depends entirely on clinical trial results and regulatory approval. This chart shows revenue projections for the biotech sector, providing context for assessing Sarepta's risks and potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772702721581 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Sarepta Therapeutics specializes in developing drugs for the treatment of rare neuromuscular diseases, particularly Duchenne muscular dystrophy. The company's success depends on regulatory approval and commercialization of its drugs. This economic outlook influences investor sentiment and their willingness to fund biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702721607 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for rare diseases, particularly Duchenne muscular dystrophy. Revenue from approved drugs is a key indicator of success. This chart illustrates the significant premium investors are willing to pay for its scientific breakthroughs and the future potential of its development pipeline.
P/S market segment - Dna
Sarepta Therapeutics is a biotech company focused on developing gene therapies for rare neuromuscular diseases, primarily Duchenne muscular dystrophy. Their innovative approaches offer hope to thousands of patients. This chart shows the average revenue estimate for the DNA therapeutics sector, reflecting investor expectations for Sarepta's breakthrough technologies.
P/S of the market as a whole
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. The company is a pioneer in its field. This chart highlights how a biotech company's valuation based on the potential of its drugs can differ from the average market revenue estimate.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases, such as Duchenne muscular dystrophy. For a biotech company with unique drugs, valuation based on future revenue is key. It reflects investors' high expectations for sales of current and future life-changing drugs.
%20P%2FS%20Sarepta%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sarepta-Therapeutics-Inc.&v=1772702721661 "The graph of the company's future (projected) P/S Sarepta Therapeutics Inc.")
Future (projected) P/S of the market segment - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases, primarily Duchenne muscular dystrophy. This chart compares the company's estimated future revenue to the biotech sector. It shows how investors view the scientific potential of its platform and the commercial prospects of its drug candidates.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772702721682 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Sarepta Therapeutics develops gene therapy for rare neuromuscular diseases. It's a science-intensive business whose prospects depend on the success of clinical trials. It represents a sector of biotechnology that is creating future markets that could radically change the forecasts shown in the chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702721688 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sarepta Therapeutics Inc.
This chart shows the revenue of Sarepta Therapeutics, a biotech company focused on developing drugs to treat rare neuromuscular diseases, specifically Duchenne muscular dystrophy. Revenue is generated from sales of its approved drugs. Growth is directly dependent on successful commercialization and expanded patient access to therapy.
Sales of companies in the market segment - Dna
Sarepta Therapeutics is a leader in developing gene therapies for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. The company's sales profile shows which of its approved drugs contributes the most to revenue, allowing for an assessment of the commercial success of its innovative treatments.
Overall market sales
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases. The company's success depends on scientific discoveries and regulatory approval, not the state of the economy. This chart illustrates general market trends, while biotech companies like Sarepta operate in their own cycle of innovation and clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for the treatment of rare neuromuscular diseases, primarily Duchenne muscular dystrophy. The company's future revenue is entirely dependent on the approval and successful launch of its innovative drugs. This chart shows analysts' forecasts for potential sales of Sarepta's medications.
%20sales%20of%20the%20company%20Sarepta%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sarepta-Therapeutics-Inc.&v=1772702721703 "Schedule of future (projected) sales of the company Sarepta Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases. This chart shows sales forecasts for the biotech sector. Is a breakthrough in genetic engineering expected to spur growth for the entire market? This allows us to assess the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772702721714 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Sarepta Therapeutics is a biotechnology company specializing in the development of gene therapies for the treatment of rare neuromuscular diseases. Its value and prospects depend solely on clinical trial success and regulatory approvals. The general economic trends reflected in this chart do not directly impact its research activities.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702721721 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing drugs to treat rare neuromuscular diseases, particularly Duchenne muscular dystrophy. This chart shows the financial trajectory of a biotech company with unique drugs. Profitability depends on regulatory approval and the ability to command high prices for life-saving, unique medications.
Market segment marginality - Dna
Sarepta Therapeutics, Inc. is a biotechnology company specializing in the development of gene therapies for the treatment of rare neuromuscular diseases, particularly Duchenne muscular dystrophy. This metric reflects the financial health of the company as a leader in its niche, where the high cost of innovative drugs and the lack of competition create the potential for high profitability.
Market marginality as a whole
Sarepta Therapeutics specializes in developing drugs for rare neuromuscular diseases. As a biotech company, it relies on investment in research and successful clinical trials. This total return chart reflects investors' risk appetite, which increases during periods of economic recovery, making it easier to raise capital.
Employees in the company, segment and market as a whole
Number of employees in the company Sarepta Therapeutics Inc.
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases. Its team of scientists and clinicians is its greatest asset. This chart shows how the biotech company is expanding its staff as it advances its drugs through the expensive clinical trials and preparations for commercial launch.
Share of the company's employees Sarepta Therapeutics Inc. within the market segment - Dna
Sarepta Therapeutics is a pioneer in RNA-based therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. Its focus is on scientific research, which requires a team of highly qualified scientists. This chart shows the company's market share in the biotech industry, and its dynamics reflect progress in clinical trials and R&D.
Number of employees in the market segment - Dna
Sarepta Therapeutics specializes in developing gene therapies for rare neuromuscular diseases such as Duchenne muscular dystrophy. This chart shows employment in the gene engineering sector. The rapid growth in the number of scientists in this field reflects scientific breakthroughs and significant investments in the technologies that form the foundation of Sarepta's business.
Number of employees in the market as a whole
Sarepta Therapeutics is a biotech company specializing in gene therapy for rare neuromuscular diseases. Its growing staff of scientists and researchers is a sign of progress in medicine. Compared to the overall employment shown in this chart, Sarepta's hiring demonstrates investors' faith in breakthrough biotechnologies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics is a leader in the treatment of Duchenne muscular dystrophy. This chart is the quintessential example of intellectual capital valuation in biotech. The company's entire value is captured in its unique drugs and scientific platform. Their astronomical market capitalization per employee reflects their dominant position in this rare disease and their enormous potential.
%20of%20the%20company%20Sarepta%20Therapeutics%20Inc.%20(SRPT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sarepta-Therapeutics-Inc.-SRPT&v=1772702721863 "Chart of market capitalization per employee (in thousands of dollars) of the company Sarepta Therapeutics Inc. (SRPT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Sarepta Therapeutics (SRPT) is a biotech pioneering the treatment of Duchenne muscular dystrophy (DMD) using RNA-targeted therapies. It is an R&D-focused company. This chart shows the industry average cost per employee. It helps estimate the premium the market pays for their scientific platform and commercial drugs in this complex niche.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772702721884 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Sarepta Therapeutics is a biotech company specializing in the treatment of rare neuromuscular diseases, such as Duchenne muscular dystrophy. Its valuation is based on unique gene therapies. The chart demonstrates a significant valuation per employee, as the market factors in the potential of revolutionary drugs that can change patients' lives.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702721909 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sarepta Therapeutics Inc. (SRPT)
Sarepta is a leader in gene therapy, focusing on the treatment of Duchenne muscular dystrophy. It boasts cutting-edge, yet also the most expensive, R&D in biotech. This chart shows how successfully the company has commercialized its first drugs. It reflects whether the research team is already capable of generating revenue sufficient to cover the enormous research costs.
%20Chart%20Sarepta%20Therapeutics%20Inc.%20(SRPT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sarepta-Therapeutics-Inc.-SRPT&v=1772702721974 "Company Profit Per Employee (in thousands of dollars) Chart Sarepta Therapeutics Inc. (SRPT)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Sarepta (SRPT) is an R&D biotech (a leader in the treatment of Duchenne). This chart shows the benchmark for "DNA" (biotech). The average profit per employee in this sector (biotech) is astronomical. It's a "blockbuster business." A single successful patent for a drug for a rare disease (with a very high price tag) can generate billions.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772702722025 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Sarepta Therapeutics is a biotech company, a leader in the treatment of Duchenne muscular dystrophy. It's an R&D company with approved, but very expensive, drugs. This chart illustrates a complex balance sheet. It reflects how much profit from current sales covers the enormous R&D costs (for new gene therapies) per scientist and employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702722073 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics is a biotech company specializing in rare genetic diseases. This chart vividly illustrates the economics of biotech. High revenue per employee is the result of bringing to market a unique, high-value drug developed by a small team of highly skilled scientists, reflecting the value of their intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sarepta-Therapeutics-Inc.-SRPT&v=1772702722130 "Sales chart per company employee Sarepta Therapeutics Inc. (SRPT)")
Sales per employee in the market segment - Dna
Sarepta Therapeutics is a biotech company specializing in gene therapy for rare neuromuscular diseases (such as Duchenne muscular dystrophy). It's at the forefront of R&D. This chart shows the average revenue in the sector. For SRPT, which already has approved drugs, this is an indicator: how much revenue per employee do their ultra-expensive treatments generate?
Sales per employee for the market as a whole
Sarepta Therapeutics is a biotech company focused on gene therapy for rare diseases (such as Duchenne muscular dystrophy). Their drugs represent scientific breakthroughs, costing a significant amount of money. This indicator demonstrates how effectively their R&D and small commercialization team can generate revenue from these extremely expensive treatments.
Short shares by company, segment and market as a whole
Shares shorted by company Sarepta Therapeutics Inc. (SRPT)
Sarepta (SRPT) is a biotech company specializing in gene therapy for rare diseases, primarily Duchenne muscular dystrophy. This chart shows the number of short positions. Short positions in SRPT are often linked to skepticism about the effectiveness of its expensive drugs, concerns about regulatory decisions (FDA), or potential competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sarepta-Therapeutics-Inc.-SRPT&v=1772702722269 "Short Shares Chart for the Company Sarepta Therapeutics Inc. (SRPT)")
Shares shorted by market segment - Dna
Sarepta Therapeutics (SRPT) is a biotech company specializing in gene therapy for rare neuromuscular diseases, primarily DMD. This chart aggregates short positions in the gene therapy sector. It reflects investor skepticism about the long-term effectiveness and commercial success of these expensive treatments.
Shares shorted by the overall market
Sarepta (SRPT) is a biotech focused on rare genetic diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often sell off when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics is a leader in developing gene therapy for Duchenne muscular dystrophy. Its shares are highly volatile and dependent on FDA decisions. A chart above 70 may reflect positive FDA news or trial data. A range below 30 is often associated with regulatory delays or safety concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sarepta-Therapeutics-Inc.-SRPT&v=1772702722286 "RSI 14 indicator chart for the company's stock Sarepta Therapeutics Inc. (SRPT)")
RSI 14 Market Segment - Dna
Sarepta (SRPT) is a biotech company focused on gene therapy for Duchenne muscular dystrophy (DMD). The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is SRPT's volatility a reaction to its trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
Sarepta (SRPT) is a biotech company. Like everything in its sector, it's critically dependent on this curve. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SRPT (Sarepta Therapeutics Inc.)
Sarepta Therapeutics is a biotech leader in the treatment of Duchenne muscular dystrophy (DMD). The company is developing gene therapy and RNA-based therapies for this rare disease. This chart reflects analyst consensus. Their target prices are based on clinical trial data, FDA approvals, and the potential market penetration of their DMD therapies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SRPT-Sarepta-Therapeutics-Inc.&v=1772702722319 "A chart showing analyst consensus forecasts for the expected stock price. SRPT (Sarepta Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price SRPT (Sarepta Therapeutics Inc.)
Sarepta Therapeutics is a biotech leader that has revolutionized the treatment of Duchenne muscular dystrophy (DMD). They are pioneers in gene therapy for this rare and fatal disease. This chart shows how much analysts believe in their controversial yet revolutionary technology and the commercial potential of their drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SRPT-Sarepta-Therapeutics-Inc.&v=1772702722322 "A chart showing the difference between the consensus forecast and the actual stock price. SRPT (Sarepta Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Sarepta Therapeutics is a leader in genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). The company is a pioneer in RNA and gene therapy. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe in the long-term success of their breakthrough drugs.
Analysts' consensus forecast for the overall market share price
Sarepta Therapeutics is a pioneer in gene therapy for rare diseases, primarily Duchenne muscular dystrophy (DMD). Their business is groundbreaking, but incredibly expensive, science. This chart shows overall market sentiment. For Sarepta, as a biotech leader, it's important to understand how overall risk appetite (analyst sentiment) influences their R&D funding and regulatory decisions. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sarepta Therapeutics Inc.
Sarepta (SRPT) is a biotech leader in rare genetic diseases, dominating the treatment of Duchenne muscular dystrophy (DMD). They are a breakthrough company. This chart is an indicator of their R&D platform. Its valuation is a binary bet on FDA approval of their breakthrough (and incredibly expensive) gene therapies, which could change patients' lives.
AKIMA Market Segment Index - Dna
Sarepta (SRPT) is a biotech leader and a pioneer in the treatment of Duchenne muscular dystrophy (DMD), developing breakthrough gene therapies for this rare disease. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Sarepta's ultra-niche (DMD) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Sarepta Therapeutics is a leader in genetic medicine for rare diseases, particularly Duchenne muscular dystrophy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative company, commercializing complex gene therapies, compares to overall economic trends.
